A total of 23 of 231 individuals in the lenalidomide group discontinued therapy due to adverse events. Two of 143 patients in the placebo group who didn’t cross to lenalidomide discontinued therapy due to adverse events, and 5 of 86 sufferers in the placebo group who crossed to lenalidomide discontinued therapy due to adverse events . After randomization, 8 new hematologic cancers and 10 solid-tumor cancers were diagnosed among the 231 patients in the lenalidomide group . The corresponding numbers of fresh hematologic and solid-tumor cancers among the 229 individuals in the placebo group had been 1 and 5 . The median time to the analysis of a hematologic malignancy after randomization was 28 weeks in sufferers in the lenalidomide group, and the 1 hematologic cancers that occurred in an individual in the placebo group was diagnosed at 30 months.Selected bacteria were regarded as contaminants. A viral pathogen was determined to be present if adenovirus, coronavirus, HMPV, human being rhinovirus, influenza virus, parainfluenza virus, or RSV was detected in a nasopharyngeal or oropharyngeal swab through PCR assay or if a pathogen-particular antibody titer was increased by one factor of 4 or more between the acute-stage serum specimen and the convalescent-phase serum specimen for all viruses except individual rhinovirus and coronaviruses. Fungal or mycobacterial detections had been determined according to scientific guidelines . Statistical Evaluation July 1 Annual incidence rates were calculated from, 2010, to June 30, 2011, july 1 and from, 2011, to June 30, 2012. The amount of enrolled adults with radiographic evidence of pneumonia was adjusted, according to generation, for the proportion of eligible adults enrolled at each research site and for the estimated proportion of admissions of adults for pneumonia to study hospitals in the catchment area .
Next Post: Kazuhiko Nakagawa.